Mesoblast 4c. If Mesoblast enters into a binding transaction in the next quarter, Mesoblast expects that one effect of the transaction is that its cash reserves are likely to increase. The highlight of the quarter was the commercial launch of Ryoncil® (remestemcel-L) in the United States. Mesoblast plans to meet with FDA to discuss the clinical data to support regulatory approval for REVASCOR in children with this life-threatening condition. mesoblast. Mesoblast has onboarded more than 25 transplant centers since product launch and expects during this quarter to complete the onboarding process across all 45 priority transplant centers that account for approximately 80% of U. . Ryoncil ® is the first and only FDA approved Jul 18, 2025 · A copy of the Appendix 4C – Quarterly Cash Flow Report for the fourth quarter FY2025 is available on the investor page of the company’s website www. About Mesoblast Oct 31, 2024 · A copy of the Appendix 4C – Quarterly Cash Flow Report for the first quarter FY2025 is available on the investor page of the company’s website www. *Mesoblast is in advanced negotiations with selected pharmaceutical companies with respect to potential partnering of certain Tier 1 product candidates. Apr 30, 2025 · Mesoblast anticipates onboarding an additional ten priority transplant centers in the current quarter. xcu wbmsb7 p9 tlzb sps ag z6 vgt4n t8 6e192